Hormone receptor status as an independent variable affecting the survival of advanced breast cancer patients with brain metastases.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to Hakan Harputluoglu.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Metastasis to the skeleton frequently occurs in breast carcinoma patients resulting in different skeletal-related events including pain, hypercalcemia, pathological fracture, and spinal cord or nerve root compression. Bisphosphonates are class of agents most frequently used to reduce skeletal-related events in patients with bone metastases by inhibiting osteoclast activity through inhibition of mevolanate pathway which is also important in cholesterol synthesis. Statins are cholesterol lowering agents and inhibit the same pathway. Therefore statins may also reduce skeletal-related events in breast cancer patients with bone metastases by inhibiting osteoclastic activity.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
For most of the patients with cancer comorbidity had independent prognostic effect. This negative influence of comorbidity on survival of cancer might be due to several mechanisms: the increased risk of death due to the comorbid condition itself, more contra-indications for anti-cancer treatment, more indications for dose reduction and a higher rate of treatment-related complications, such as infections and cardiovascular events. It is known that in some chronic diseases (e.g., coronary artery disease, hypertension, and obesity) pro-angiogenic growth factors are increased compared to controls and mostly normalized after specific treatment. We propose that increased pro-angiogenic growth factor levels in cancer patients due to comorbidities may lead to the progression of the tumors and poor prognosis. Treatment of comorbidities besides the treatment of primary tumor may further increase effective management of cancer.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.